Immunogenicity and In Vivo Protective Effects of Recombinant Nucleocapsid-Based SARS-CoV-2 Vaccine Convacell(®)

The vast majority of SARS-CoV-2 vaccines which are licensed or under development focus on the spike (S) protein and its receptor binding domain (RBD). However, the S protein shows considerable sequence variations among variants of concern. The aim of this study was to develop and characterize a SARS...

Descripción completa

Detalles Bibliográficos
Autores principales: Rabdano, Sevastyan O., Ruzanova, Ellina A., Pletyukhina, Iuliia V., Saveliev, Nikita S., Kryshen, Kirill L., Katelnikova, Anastasiia E., Beltyukov, Petr P., Fakhretdinova, Liliya N., Safi, Ariana S., Rudakov, German O., Arakelov, Sergei A., Andreev, Igor V., Kofiadi, Ilya A., Khaitov, Musa R., Valenta, Rudolf, Kryuchko, Daria S., Berzin, Igor A., Belozerova, Natalia S., Evtushenko, Anatoly E., Truhin, Viktor P., Skvortsova, Veronika I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10141225/
https://www.ncbi.nlm.nih.gov/pubmed/37112786
http://dx.doi.org/10.3390/vaccines11040874

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10141225/
https://www.ncbi.nlm.nih.gov/pubmed/37112786
http://dx.doi.org/10.3390/vaccines11040874

Ejemplares similares